Kuldeep Neote
Company: Diadem Biotherapeutics
Job title: CEO
Bio:
Dr Kuldeep Neote is the CEO of Diadem Biotherapeutics. Previously, Dr. Kuldeep Neote was Vice President, External Innovation at Eli Lilly and responsible for Lilly’s New Venture initiative. During his tenure at Lilly, he focused on precision and genomic based therapeutics opportunities and enabled Lilly’s recent acquisition of Prevail Therapeutics. From 2013-2018, he was Senior Director, New Ventures at Johnson & Johnson Innovation and responsible for New Venture activities for the Janssen R&D in the East Coast. Prior to Eli Lilly, he was a Discovery Scientist in Pfizer Inc. in Groton, CT. Dr. Neote initiated the Chemokine Receptor Drug Discovery platform that led to several clinical candidates, and also discovered novel chemokines. Earlier in his career, Dr. Neote cloned one of the first chemokine receptors during his post-doctoral studies in Genentech.
Seminars:
Panel Discussion: Accelerating Scalable & Cost-Effective Extra-Cellular Vesicle Manufacturing for the Development of Therapeutics for Regenerative, Precision & CGT Therapies 11:30 am
Exploring cost-efficient exosome sources such as bodily fluids to reduce the high production costs associated with cellderived exosomes Understanding the complexities involved in setting up pipelines for the purification and production of engineered exosomes to optimize cost considerations throughout the development process Delving into the factors contributing to the cost of engineered exosomes, including production…Read more
day: Conference Day Two
Chair’s Closing Remarks 4:30 pm
day: Conference Day Two